anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing a Crepidiastrum denticulatum extract for reducing body weight and preventing and treating obesity is provided to reduce TNF-alpha and IL-6 expression. CONSTITUTION: A composition for preventing and treating obesity and reducing body weight contains a Crepidiastrum denticulatum extract as an active ingredient. The extract is prepared using water, an organic solvent, or a mixture thereof. The organic solvent is selected from the group consisting of alcohol, ethyl acetate, methylene chloride, and chloroform. The alcohol is C1-C4 alcohol. [Reference numerals] (AA) Weight(g); (BB) Normal diet; (CC) High fat diet; (DD) High fat diet + Crepidiastrum denticulatum extract; (EE) High fat diet + Milk thistle extract; (FF) Weeks;
Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study lasts 15 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
Aspirin is associated with serious gastrointestinal (GI) adverse reactions, including inflammation, bleeding ulceration and perforation of the upper and lower GI tract. Other adverse reactions with aspirin include stomach pain, heartburn, nausea, and vomiting. 

Serious GI adverse reactions reported in the clinical trials of YOSPRALA were: gastric ulcer hemorrhage in one of the 521 patients treated with YOSPRALA and duodenal ulcer hemorrhage in one of the 524 patients treated with enteric-coated aspirin. In addition, there were two cases of intestinal hemorrhage, one in each treatment group, and one patient treated with YOSPRALA experienced obstruction of the small bowel.

Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, monitor patients for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Inform patients about the signs and symptoms of GI adverse reactions. If active and clinically significant bleeding from any source occurs in patients receiving YOSPRALA, discontinue treatment.
PURPOSE OF REVIEW: To provide an approach to perioperative fluid management for lung resection patients that incorporates the entire patient pathway in the context of international guidelines on enhanced recovery after surgery (ERAS).
RECENT FINDINGS: The concern with intraoperative fluid management is that giving too little or too much fluid is associated with worse outcomes after lung resection. However, it has not emerged as a key care element in thoracic ERAS programs probably due to the influence of other ERAS elements. Carbohydrate loading 2 h before surgery and the allowance of water until just prior to induction ensures the patient is both well hydrated and metabolically normal when they enter the operating room. Consequently, maintaining a euvolemic state during anesthesia can be achieved without goal-directed fluid therapy despite the recommendations of some guidelines. Intravenous fluids can be safely stopped in the immediate postoperative period.
SUMMARY: The goal of perioperative euvolemia can be achieved with the ongoing evolution and application of ERAS principles. A focus on the pre and postoperative phases of fluid management and a pragmatic approach to intraoperative fluid management negates the need for goal-directed fluid therapy in most cases.
Alzheimer's disease is a common condition affecting memory and thinking. Genes can sometimes be used to provide risk estimates for the eventual development of certain common diseases. Apolipoprotein E (APOE) is one gene which can provide information about a person's chances of developing Alzheimer's disease.

Some people with a diagnosis of Mild Cognitive Impairment (MCI) are curious to learn more about the chance of developing Alzheimer's disease. In the REVEAL IV Study, we are examining the psychological and behavioral impact of learning genetic risk information pertaining to the chance for an individual with MCI to progress to dementia of the Alzheimer's type within three years.

Participation in this study requires an initial phone call which will elicit some demographic information about the participant and his or her study partner. A first in-person visit to the research clinic will consist of an education session, the administration of knowledge and attitudinal surveys and some tests to assess memory and thinking skills. This visit will take approximately 2-3 hours. Participants with MCI will have their blood drawn for genetic testing. Participants will then be randomized to one of two groups. Those in the intervention arm will receive a three-year risk estimate for the chance of progressing to dementia of the Alzheimer's type based on age, the diagnosis of MCI and their own APOE gene test result. Those in the comparison arm will receive a three-year risk estimate for the chance of progressing to dementia of the Alzheimer's type based on age and the diagnosis of MCI, without the APOE gene test result. Participants randomized to the comparison arm will have the opportunity to learn their own APOE gene test result at the end of the study. Participants and their study partners will be followed for 6 months following disclosure of results with 1 additional clinic visit and 1 additional phone interviews.
A physiological sensor controller controls a physiological sensor (or ECG sensor), positioned on a patient body, for measuring physiological information (or ECG waveform) of the patient body to output a measurement signal. An acquisition device acquires a verification image containing portions of identification information of the physiological sensor and a face of the patient body. A verifier performs verification of acceptability in a combination of the physiological sensor and the patient body according to the verification image. A receiver receives the measurement signal. A detector detects normality or abnormality of receptivity of the measurement signal. A checker operates assuming that the detector determines the abnormality of the receptivity, and checks whether a retry for the verification in the verifier is required or not. An output device operates assuming that the checker determines requirement of the retry for the verification, and outputs information of encouraging the retry for the verification.
A method for providing an intelligent schedule board for operating rooms in surgical centers and hospitals is provided. The method comprises displaying an estimated location of a patient on an operating room schedule board and displaying status information on the operating room schedule board. The method also comprises automatically updating the schedule dashboard as at least one of the location and the status of the patient changes. Patient location is estimated using an indoor tracking system and wherein the system is an RTLS system. Patient status information is entered by staff members by means of at least one of a tablet device, a phone device, and a computer. Patient status information is entered automatically by means of a computer vision scheme that detects patient status comprising at least one of a start of surgery and an end of surgery. Patient status information is entered using a voice recognition scheme.
Cervical cancer remains one of the most common cancers in women in terms of both incidence and mortality. Human Papilloma Virus carriage is a necessary condition for the development of these cancers but is not the only factor responsible for malignant transformation. Numerous molecular alterations come into play in the development of these tumours, involving the activation of oncogenes or the inactivation of tumour suppressor genes. Treatment of locally-advanced cancer is based on radiotherapy or a combination of radiotherapy and chemotherapy. Responses to anti-neoplastic treatments remain very heterogeneous from one woman to another. Predicting the response to these treatments would make it possible to envisage early therapeutic alternatives for patients identified as not very sensitive to standard treatments. IAPs (inhibitors of apoptosis proteins), which include XIAP, cIAP1 and cIAP2, are proteins involved in many cancers and capable of downregulating tumour cell apoptosis. It seems justified to investigate the role of these IAPs in resisting apoptosis-inducing anti-neoplastic treatments such as chemotherapy or radiotherapy. The aim of our study is to assess the prognostic role of overexpression of IAPs in locally advanced cervical cancer treated exclusively with radio-chemotherapy. This research seems all the more important as IAP-inhibiting molecules are currently being studied in other types of cancer (ear, nose and throat cancers) and appear to have a very encouraging radiosensitising effect. The hypothesis is that overexpression of IAPs in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy has a prognostic role on the local recurrence rate at 24 months.
Non-pharmacological treatment including Korean medicine will be implemented to the participants for total 8 weeks. This is a pragmatic clinical trial, and the specific intervention will be determined according to the physician's choice. intervention data will be recorded in the case report form.
BACKGROUND: Strictly superficial cerebellar microbleeds and cerebellar superficial siderosis have been considered markers of advanced cerebral amyloid angiopathy (CAA), but there are few studies on cerebellar ischemic lesions in CAA. We investigated the presence of superficial small cerebellar infarct (SCI) ≤15 mm and its relation to magnetic resonance imaging (MRI) markers in patients with probable CAA.
METHODS: Eighty patients with probable CAA were retrospectively evaluated. The presence of superficial SCIs was examined, along with cerebellar microbleeds and cerebellar superficial siderosis, using 3-T MRI. Lobar cerebral microbleeds, cortical superficial siderosis (cSS), enlargement of the perivascular space in the centrum semiovale, and white matter hyperintensity were assessed and the total CAA-small vessel disease (SVD) score was calculated.
RESULTS: Nine of the 80 patients (11.3%) had a total of 16 superficial SCIs. By tentatively defining SCI <4 mm as cerebellar microinfarcts, 8 out of 16 (50%) superficial SCIs corresponded to cerebellar microinfarcts. The total CAA-SVD score was significantly higher in patients with superficial SCIs (p = 0.01). The prevalence of cSS (p = 0.018), cortical cerebral microinfarct (p = 0.034), and superficial cerebellar microbleeds (p = 0.006) was significantly higher in patients with superficial SCIs. The number of superficial cerebellar microbleeds was also significantly higher in patients with superficial SCIs (p = 0.001).
CONCLUSIONS: Our results suggest that in patients with CAA, superficial SCIs (including microinfarcts) on MRI may indicate more severe, advanced-stage CAA. These preliminary findings should be verified by larger prospective studies in the future.
Short-chain fatty acids (SCFAs) are essential molecules produced by gut bacteria that fuel intestinal cells and may also influence overall health. An imbalance of SCFAs can result in various acute and chronic diseases, including diabetes, obesity and colorectal cancer (CRC). This review delves into the multifaceted roles of SCFAs, including a brief discussion on their source and various gut-residing bacteria. Primary techniques used for detection of SCFAs, including gas chromatography, high-performance gas chromatography, nuclear magnetic resonance and capillary electrophoresis are also discussed through this article. This review study also compiles various synthesis pathways of SCFAs from diverse substrates such as sugar, acetone, ethanol and amino acids. The different pathways through which SCFAs enter cells for immune response regulation are also highlighted. A major emphasis is the discussion on diseases associated with SCFA dysregulation, such as anaemia, brain development, CRC, depression, obesity and diabetes. This includes exploring the relationship between SCFA levels across ethnicities and their connection with blood pressure and CRC. In conclusion, this review highlights the critical role of SCFAs in maintaining gut health and their implications in various diseases, emphasizing the need for further research on SCFA detection, synthesis and their potential as diagnostic biomarkers. Future studies of SCFAs will pave the way for the development of novel diagnostic tools and therapeutic strategies for optimizing gut health and preventing diseases associated with SCFA dysregulation.
The invention discloses an externally used Chinese medicine preparation for curing viral dermatoses and a preparation method. The externally used Chinese medicine preparation includes, by mass, 40-45% of bitter gynostemma pentaphyllum, 18-23% of sophora flavescens, 18-23% of barbed skullcap herb, 1-1.5% of borneol, 2-3% of azone and 20-25% of ethanol. The sum of mass percentages of all components is 100%. The preparation method includes weighing the gynostemma pentaphyllum, the sophora flavescens and the barbed skullcap herb, adding water, decocting, filtering and removing slag, and performing concentration; adding 95% of ethanol, performing cold storage and standing, and filtering; recycling the ethanol and performing concentration; and adjusting ethanol content of the solution and adding the borneol and the azone to obtain the finished product. The externally used Chinese medicine preparation is rich in medical herb resource, safe and non-toxic, convenient to use and wide in application range, and has good development prospect. More than 20 years of clinical applications prove that the externally used Chinese medicine preparation has good therapeutic effects on viral dermatoses such as herpes zoster, varicella, prurigo, pompholyx, condyloma acuminatum and genital herpes.
NEW MATERIAL:A compound shown by formula I [C is OH or OSO3H; one of Y and Z is OSO3H and the other is H; R1 is H or lower alkyl; when Y is H, one of R2 and R3 is H and the other is lower alkyl or group shown by formula II (R5 and R6 are lower alkyl); when Z is H, R2 is H; both R2 and R3 show lower alkyl or one of R2 and R3 is H and the other is lower alkyl or group shown by formula II]. EXAMPLE:6-Methyl-1,4-heptanediol-4-sulfate. USE:Showing enhancing effects on actions of beta-adrenergic drug and useful as a cardiac. Having bronchodilatory action and useful as a drug for asthma. Usable as a substitute for musk which is difficult to obtain. PREPARATION:For example, 2,3-dihydrofuran is hydrolyzed, reacted with Grignard reagent, tritylated, sulfonylated and detritylated to give an example compound among compounds shown by formula I.
Use of lysine derivatives (I), or their acceptable salts for treatment and/or prevention of inflammatory diseases. Use of lysine derivatives of formula (I), or their acceptable salts, for treatment and/or prevention of inflammatory diseases. X : hydroxy, amino, alkoxy, Pro or Pro-Thr (I) may be N-acylated and/or C-amidated or -esterified. An independent claim is also included for in vitro preparation of cells that can impart tolerance to an antigen (Ag) by treating antigen-presenting cells (APC) with alpha-melanocyte stimulating hormone (aMSH), or its biologically active fragments or derivatives, and with Ag, in either order or simultaneously. [Image] ACTIVITY : Antiinflammatory; Antiallergic; Immunosuppressive; Antifibrotic; Dermatological; Antipsoriatic; Antiasthmatic; Antiulcer. Mice were sensitized to the hapten DNFB, then (after 7 days) the same hapten was applied to the ear, and after a further 24 hr the swelling of the ear was measured. The mean value was 7 (mmX10 -2>), but only 1 when the mice had been injected, intraperitoneally, with an unspecified dose of Lys-Pro-Thr, 2 hr before sensitization. The treated animals did not respond to a second sensitization/challenge, showing that tolerance had been induced. MECHANISM OF ACTION : (I) inhibits activation of the NF-kappaB transcription factor by cytokines or lipopolysaccharide; Reduces expression of costimulatory molecules from dendritic cells and increases production of interleukin-10 from monocytes. (I) may bind to the beta -adrenergic and type 1 interleukin-1 receptors, possibly also to other receptors.
Experience with overdose of dasatinib in clinical studies is limited to isolated cases. The highest overdosage of 280 mg per day for 1 week was reported in two patients and both developed severe myelosuppression and bleeding. Since dasatinib is associated with severe myelosuppression [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)], monitor patients who ingest more than the recommended dosage closely for myelosuppression and give appropriate supportive treatment.

Acute overdose in animals was associated with cardiotoxicity. Evidence of cardiotoxicity included ventricular necrosis and valvular/ventricular/atrial hemorrhage at single doses ≥100 mg/kg (600 mg/m2) in rodents. There was a tendency for increased systolic and diastolic blood pressure in monkeys at single doses ≥10 mg/kg (120 mg/m2).
The Herpesviridae include the Epstein-Barr Virus (EBV) and the Kaposi Sarcoma-associated Herpesvirus (KSHV), both of which are oncogenic gamma-herpesviruses. These viruses manipulate host cellular mechanisms, including through ubiquitin-mediated pathways, to promote viral replication and oncogenesis. Ubiquitin, a regulatory protein which tags substrates for degradation or alters their function, is manipulated by both EBV and KSHV to facilitate viral persistence and cancer development. EBV infects approximately 90% of the global population and is implicated in malignancies including Burkitt lymphoma (BL), Hodgkin lymphoma (HL), post-transplant lymphoproliferative disorder (PTLD), and nasopharyngeal carcinoma. EBV latency proteins, notably LMP1 and EBNA3C, use ubiquitin-mediated mechanisms to inhibit apoptosis, promote cell proliferation, and interfere with DNA repair, contributing to tumorigenesis. EBV's lytic proteins, including BZLF1 and BPLF1, further disrupt cellular processes to favor oncogenesis. Similarly, KSHV, a causative agent of Kaposi's Sarcoma and lymphoproliferative disorders, has a latency-associated nuclear antigen (LANA) and other latency proteins that manipulate ubiquitin pathways to degrade tumor suppressors, stabilize oncogenic proteins, and evade immune responses. KSHV's lytic cycle proteins, such as RTA and Orf64, also use ubiquitin-mediated strategies to impair immune functions and promote oncogenesis. This review explores the ubiquitin-mediated interactions of EBV and KSHV proteins, elucidating their roles in viral oncogenesis. Understanding these mechanisms offers insights into the similarities between the viruses, as well as provoking thought about potential therapeutic targets for herpesvirus-associated cancers.
Systemic inflammation is related to disease progression and prognosis in patients with advanced cirrhosis. However, the mechanisms underlying the initiation of inflammation are still not fully understood. The role of CD169+ monocyte/macrophage in cirrhotic systemic inflammation was undetected. Flow cytometry analysis was used to detect the percentage and phenotypes of CD169+ monocytes as well as their proinflammatory function in patient-derived cirrhotic tissue and blood. Transcriptome differences between CD169+ and CD169- monocytes were also compared. Additionally, a mouse model with specific depletion of CD169+ monocytes/macrophages was utilized to define their role in liver injury and fibrosis. We observed increased CD169 expression in monocytes from cirrhotic patients, which was correlated with inflammatory cytokine production and disease progression. CD169+ monocytes simultaneously highly expressed M1- and M2-like markers and presented immune-activated profiles. We also proved that CD169+ monocytes robustly prevented neutrophil apoptosis. Depletion of CD169+ monocytes/macrophages significantly inhibited inflammation and liver necrosis in acute liver injury, but the spontaneous fibrin resolution after repeated liver injury was impaired. Our results indicate that CD169 defines a subset of inflammation-associated monocyte that correlates with disease development in patients with cirrhosis. This provides a possible therapeutic target for alleviating inflammation and improving survival in cirrhosis.
We aimed to investigate the relationship between the risk of oral frailty and awareness of oral frailty among Japanese adults in an adult dental health field study conducted in Kanagawa Prefecture. Questionnaire data from a total of 5051 individuals (1907 males, 3144 females; mean age; 59.9 years) were used. The risk of oral frailty was assessed using the Oral Frailty Index-8. Of the participants, 1418 (28.1%) had a high risk of oral frailty and 1495 (29.6%) had knowledge of oral frailty. Logistic regression analysis indicated that the risk of oral frailty was significantly associated with awareness of oral frailty. We further found that awareness of oral frailty was significantly related to gender (female), age (20-39 compared to 70-79, ≥ 80), residential areas (Yokohama compared to Kawasaki, Sagamihara), exercise habits (yes), eating a balanced diet (yes), consciousness of oral health (yes), risk of oral frailty (low) and outpatient category (hospital visit). For groups with low levels of awareness obtained from the results of this study, it is necessary to consider the means of accessibility and increase awareness further.
A nozzle includes a nozzle body having a fluid passageway to which extension tubes are communicated. Each extension tube includes an end having an outlet port. The outlet ports are spaced from each other. An apparatus includes the nozzle, a fluid tank into which the extension tubes extends, a fluid shear device mounted in the fluid tank, and a temperature control system in which the fluid tank is mounted. A method includes filling a water phase fluid into the fluid tank. An oil phase fluid flows out of the nozzle body via the outlet ports. The water phase fluid is disturbed and flows out of the outlet ports to form semi-products of microparticles in the fluid tank. Each semi-product has an inner layer formed by the oil phase fluid and an outer layer formed by the water phase fluid. The outer layers of the semi-products are removed to form microparticles.
Participants in TNT PISP intervention group will come to once monthly educational support group sessions and will be additionally enrolled in the community based doula program where they will receive 1 on 1 doula and lactation support throughout their pregnancy, delivery, and postpartum period. They will receive prenatal care clinical visits on their own with their prenatal care provider. In phase 2 of the study, participants will be offered on site prenatal care once per month.
NEW MATERIAL:A complex of formula I (n is an integer 1-20; m is an integer 1-6; X is halogen). USE:An oxygen adsorbent. PREPARATION:A carboxylic acid chloride of formula II is reacted with 5,10,15, 20-tetra(alpha,alpha,alpha,alpha-o-aminophenyl)porphyrin of formula III in the presence of a base to give a product, which is then reacted with anhydrous aluminum chloride in the presence of anisole to remove the benzyl group therefrom and give a compound. The resultant compound is then reacted with ferrous bromide in the presence of pyridine and treated with a mineral acid, e.g. 48% hydrobromic acid, concentrated hydrochloric acid or hydriodic acid, to afford a terminal hydroxyl type complex in which the bromine ions are coordinated. The resultant complex is further reacted with itaconic acid anhydride to give a terminal carboxylic acid type complex, which is treated with triethylamine and ethyl chloroformate and then reacted with a terminal aminooligoethylene glycol of formula IV to afford the aimed complex of formula I .